BTIG Reiterates Buy Rating on Serina Therapeutics, Inc.
BTIG reaffirms its Buy rating for Serina Therapeutics with an $8 price target, a 312.37% upside from the current price.
Key Points
- BTIG reiterated a Buy rating for Serina Therapeutics, Inc. (SER) with a price target of $8 on July 1.
- BTIG's $8 price target implies 312.37% upside from Serina Therapeutics, Inc.'s ($SER) current $1.94 share price.
- Serina Therapeutics' stock traded at $1.94 on Wednesday, with a market cap of about $29.1 million and a 52-week range between $1.22 and $7.92.
- Insider buying was notable with Gregory Bailey acquiring over 8.4 million shares on June 17, indicating strong insider interest.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
BTIG reiterated its Buy rating on Serina Therapeutics, Inc. (NYSE American: SER) on July 1, maintaining a price target of $8. Analyst Thomas Shrader expressed continued confidence in the company's prospects.
BTIG vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Serina Therapeutics
SIO Capital Management, LLC opened a new position in Serina Therapeutics, acquiring 1,000,000 shares valued at approximately $1.94 million. Vanguard Capital Management LLC also initiated a stake, purchasing 159,136 shares worth around $308,724. Geode Capital Management, LLC increased its holdings by 34,564 shares, resulting in a total of 64,973 shares valued at $126,049, reflecting a 113.7% increase. BlackRock, Inc. significantly boosted its position by 41,015 shares, ending with 58,264 shares valued at $113,033, a 237.8% increase.
Serina Therapeutics, Inc. Stock Down 21.1%
Shares of NYSE American:SER traded at around $1.94 on Wednesday. Serina Therapeutics has a market capitalization of approximately $29.1 million. The stock has a 52-week low of $1.22 and a high of $7.92, with a 50-day moving average of $1.84 and a 200-day moving average of $2.89. The company's current ratio stands at 4.18, and the debt-to-equity ratio is 18.93, indicating a strong liquidity position.
$SER price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Serina Therapeutics reported revenue of $130,000, with no net margin due to ongoing investments in research and development. The company recorded a negative return on equity of -2.22%. The next earnings report is expected on August 4, 2025.
Insider Buying and Selling at Serina Therapeutics, Inc.
On June 17, several insiders made significant purchases of Serina Therapeutics stock. Gregory Bailey acquired 8,437,472 shares, while Jay Venkatesan bought 224,152 shares at an average price of $2.25. Other insiders, including Karen Wilson and Richard Peter Marshall, also participated in the buying spree, each acquiring 15,250 shares.
Analysts Set New Price Targets
On July 1, BTIG reiterated its Buy rating for Serina Therapeutics with an $8 price target. HC Wainwright & Co. had previously set a Buy rating with a $15 target on August 28, 2025. Jones Trading also initiated coverage with a Buy rating and an $11 target on March 11, 2025. Currently, the consensus target price is $11, based on one analyst's opinion.
About Serina Therapeutics
Serina Therapeutics, Inc. is a biotechnology company focused on developing treatments for neurological diseases and pain. Its lead product, SER 252, is in phase 1 clinical trials for advanced Parkinson's disease. The company also explores POZ technology for lipid nanoparticle vaccines. Founded in 2006, Serina Therapeutics is headquartered in Huntsville, Alabama, and led by CEO Steven A. Ledger.
Bottom Line
BTIG's reaffirmation of a Buy rating with an $8 target reflects confidence in Serina Therapeutics' potential. Investors watch analyst ratings for insights, though it's important to remember these are forward-looking estimates. As always, 13F filings and analyst opinions are backward-looking and may not reflect current conditions.
Get Serina Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SER, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.